MétaCan
Menu
← Back to cohort
Record W4304080447 · doi:10.1136/bmjopen-2022-061468

Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation

2022· article· en· W4304080447 on OpenAlexafffundabout
Robin Z. Hayeems, François P. Bernier, Kym M. Boycott, Taila Hartley, Christine Michaels-Igbokwe, Deborah A. Marshall

Bibliographic record

VenueBMJ Open · 2022
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicGenomics and Rare Diseases
Canadian institutionsUniversity of OttawaAlberta Children's HospitalChildren's Hospital of Eastern OntarioUniversity of CalgaryInstitute for Clinical Evaluative SciencesUniversity of TorontoSickKids FoundationHospital for Sick Children
FundersGenome AlbertaGenome British ColumbiaGénome QuébecCanadian Institutes of Health ResearchGenome CanadaChildren's Hospital of Eastern Ontario FoundationOntario GenomicsOntario Genomics Institute
KeywordsMedicineObservational studyProtocol (science)Exome sequencingCohort studyCohortDiseaseExomeEpidemiologyAlternative medicineInternal medicinePathologyGeneticsMutationGene

Abstract

fetched live from OpenAlex

INTRODUCTION: Despite the superior diagnostic performance of exome and genome sequencing compared with conventional genetic tests, evidence gaps related to clinical utility and cost effectiveness have limited their availability in routine clinical practice in many jurisdictions. To inform adoption and reimbursement policy, this protocol provides a chain of evidence approach to determining the diagnostic utility, clinical utility and cost-effectiveness of whole exome sequencing (WES) from seven medical genetic centres in two Canadian provinces. METHODS AND ANALYSIS: Using a multicentre observational cohort design, we will extract data specific to the pre-WES diagnostic pathway and 1-year post-WES medical management from electronic medical records for 650 patients with rare disease of suspected genetic aetiology who receive WES. The date from the clinical record will be linked to provincial administrative health database to capture healthcare resource use and estimate costs. Our analysis will: (1) define and describe diagnostic testing pathways that occur prior to WES among patients with rare disease, (2) determine the diagnostic utility of WES, characterised as the proportion of patients for whom causative DNA variants are identified, (3) determine the clinical utility of WES, characterised as a change in medical management triggered by WES results, (4) determine the pattern and cost of health service utilisation prior and 1 year following WES among patients who receive a diagnosis, do not receive a diagnosis, or receive an uncertain diagnosis and (5) estimate the cost-effectiveness of WES compared with conventional diagnostic testing pathways, measured by the incremental cost per additional patient diagnosed by WES using simulation modelling. ETHICS AND DISSEMINATION: This protocol was approved by Clinical Trials Ontario (CTO-1577) and research ethics boards at the University of Calgary (REB18-0744 and REB20-1449) and University of Alberta (Pro0009156). Findings will be disseminated through academic publications and policy reports.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.150
metaresearch head score (Gemma)0.177
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.150
Threshold uncertainty score0.794

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1500.177
Meta-epidemiology (narrow)0.0030.003
Meta-epidemiology (broad)0.0040.009
Bibliometrics0.0040.006
Science and technology studies0.0030.003
Scholarly communication0.0050.003
Open science0.0040.005
Research integrity0.0050.005
Insufficient payload (model declined to judge)0.0240.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.221
GPT teacher head0.459
Teacher spread0.239 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2022
Admission routes3
Has abstractyes

Explore more

Same venueBMJ Open→Same topicGenomics and Rare Diseases→French-language works237,207→